Logo

Analytik Jena Takes 20 Percent Stake in Westburg

Jul 23, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Analytik Jena has acquired 20 percent of the shares of its Dutch distribution partner, Westburg, for €150,000 ($215,272).

Based in Leusden, The Netherlands, Westburg specializes in molecular diagnostics sales and distribution. Its primary markets are the Benelux and Scandinavian countries.

"We want our market share in the life sciences in Europe [to] continue to expand and are looking for growth opportunities in targeted regions," Analytik Jena CEO Klaus Berka said in a statement.

Analytik Jena is based in Jena, Germany, and sells bioanalytical instruments and kits. It said that for the current financial year it expects revenues from its products sold by Westburg to be around €400,000.

Filed under

Diagnostics
Business News
equity investment
Analytik Jena
Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.